Hehlgans S - Search Results

1

A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin.

Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rödel C, Rödel F. Reichert S, et al. Among authors: hehlgans s. Radiother Oncol. 2012 Jun;103(3):394-401. doi: 10.1016/j.radonc.2012.03.018. Epub 2012 May 3. Radiother Oncol. 2012. PMID: 22560712

2

Integrin-linked kinase: dispensable for radiation survival of three-dimensionally cultured fibroblasts.

Hehlgans S, Eke I, Deuse Y, Cordes N. Hehlgans S, et al. Radiother Oncol. 2008 Mar;86(3):329-35. doi: 10.1016/j.radonc.2007.09.007. Epub 2007 Oct 1. Radiother Oncol. 2008. PMID: 17905456

3

Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells.

Hehlgans S, Eke I, Storch K, Haase M, Baretton GB, Cordes N. Hehlgans S, et al. Radiother Oncol. 2009 Sep;92(3):362-70. doi: 10.1016/j.radonc.2009.07.004. Epub 2009 Aug 6. Radiother Oncol. 2009. PMID: 19665245

4

3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.

Hehlgans S, Lange I, Eke I, Cordes N. Hehlgans S, et al. Radiother Oncol. 2009 Sep;92(3):371-8. doi: 10.1016/j.radonc.2009.08.001. Epub 2009 Sep 2. Radiother Oncol. 2009. PMID: 19729215

5

NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis.

Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, Vellanki SH, Hehlgans S, Rödel F, Debatin KM, Ludolph AC, Fulda S. Berger R, et al. Among authors: hehlgans s. Mol Cancer Ther. 2011 Oct;10(10):1867-75. doi: 10.1158/1535-7163.MCT-11-0218. Epub 2011 Aug 22. Mol Cancer Ther. 2011. PMID: 21859841

6

XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma.

Moussata D, Amara S, Siddeek B, Decaussin M, Hehlgans S, Paul-Bellon R, Mornex F, Gerard JP, Romestaing P, Rödel F, Flourie B, Benahmed M, Mauduit C. Moussata D, et al. Among authors: hehlgans s. Am J Pathol. 2012 Oct;181(4):1271-8. doi: 10.1016/j.ajpath.2012.06.029. Epub 2012 Aug 4. Am J Pathol. 2012. PMID: 22867709 Free article.

7

Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation.

Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, Seegenschmiedt MH, Gaipl US, Rödel C. Rödel F, et al. Among authors: hehlgans s. Front Oncol. 2012 Sep 25;2:120. doi: 10.3389/fonc.2012.00120. eCollection 2012. Front Oncol. 2012. PMID: 23057008 Free PMC article.

8

Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration.

Hehlgans S, Petraki C, Reichert S, Cordes N, Rödel C, Rödel F. Hehlgans S, et al. Radiother Oncol. 2013 Jul;108(1):32-9. doi: 10.1016/j.radonc.2013.06.006. Epub 2013 Jul 3. Radiother Oncol. 2013. PMID: 23830189

9

Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells.

Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C, Gehrmann M, Rödel C, Kreuter J, Rödel F. Gaca S, et al. Among authors: hehlgans s. J Control Release. 2013 Nov 28;172(1):201-206. doi: 10.1016/j.jconrel.2013.08.020. Epub 2013 Sep 2. J Control Release. 2013. PMID: 24008150

10

The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy.

Hehlgans S, Storch K, Lange I, Cordes N. Hehlgans S, et al. Radiother Oncol. 2013 Oct;109(1):126-32. doi: 10.1016/j.radonc.2013.08.023. Epub 2013 Sep 20. Radiother Oncol. 2013. PMID: 24060178

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters